Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Apr 3;82(9):1535–1538. doi: 10.1054/bjoc.2000.1174

Role of tumour markers in monitoring epithelial ovarian cancer

T Meyer 1, G J S Rustin 1
PMCID: PMC2363391  PMID: 10789720

Abstract

Currently the only tumour marker to have a well-defined and validated role in the management of ovarian cancer is CA125. Changes in the level of CA125 can be used as a reliable indication of response or progression according to various criteria, but it does not yet have a clear place in diagnosis or prognosis. Its value as part of a screening tool and during routine follow-up remain the subject of ongoing trials. Other markers remain experimental and do not have a well-defined contribution to make at present. © 2000 Cancer Research Campaign

Full Text

The Full Text of this article is available as a PDF (76.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  3. Bridgewater J. A., Nelstrop A. E., Rustin G. J., Gore M. E., McGuire W. P., Hoskins W. J. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999 Feb;17(2):501–508. doi: 10.1200/JCO.1999.17.2.501. [DOI] [PubMed] [Google Scholar]
  4. Buller R. E., Berman M. L., Bloss J. D., Manetta A., DiSaia P. J. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol. 1992 Oct;47(1):87–92. doi: 10.1016/0090-8258(92)90082-t. [DOI] [PubMed] [Google Scholar]
  5. Davelaar E. M., Bonfrer J. M., Verstraeten R. A., ten Bokkel Huinink W. W., Kenemans P. CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Cancer. 1996 Jul 1;78(1):118–127. doi: 10.1002/(SICI)1097-0142(19960701)78:1<118::AID-CNCR17>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  6. Einhorn N., Sjövall K., Knapp R. C., Hall P., Scully R. E., Bast R. C., Jr, Zurawski V. R., Jr Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992 Jul;80(1):14–18. [PubMed] [Google Scholar]
  7. Eisenhauer E. A., Vermorken J. B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol. 1997 Oct;8(10):963–968. doi: 10.1023/a:1008240421028. [DOI] [PubMed] [Google Scholar]
  8. Fayers P.M., Rustin G., Wood R., Nelstrop A., Leonard R.C.F., Wilkinson P., Cruickshank D., McAllister E.J., Redman C.W.E., Parker D. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer. 1993 Sep;3(5):285–292. doi: 10.1046/j.1525-1438.1993.03050285.x. [DOI] [PubMed] [Google Scholar]
  9. Gadducci A., Baicchi U., Marrai R., Ferdeghini M., Bianchi R., Facchini V. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol. 1996 Feb;60(2):197–202. doi: 10.1006/gyno.1996.0025. [DOI] [PubMed] [Google Scholar]
  10. Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999 Apr 10;353(9160):1207–1210. doi: 10.1016/S0140-6736(98)10261-1. [DOI] [PubMed] [Google Scholar]
  11. Jacobs I., Davies A. P., Bridges J., Stabile I., Fay T., Lower A., Grudzinskas J. G., Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993 Apr 17;306(6884):1030–1034. doi: 10.1136/bmj.306.6884.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J. G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990 Oct;97(10):922–929. doi: 10.1111/j.1471-0528.1990.tb02448.x. [DOI] [PubMed] [Google Scholar]
  13. Jacobs I., Stabile I., Bridges J., Kemsley P., Reynolds C., Grudzinskas J., Oram D. Multimodal approach to screening for ovarian cancer. Lancet. 1988 Feb 6;1(8580):268–271. doi: 10.1016/s0140-6736(88)90351-0. [DOI] [PubMed] [Google Scholar]
  14. Krebs H. B., Goplerud D. R., Kilpatrick S. J., Myers M. B., Hunt A. Role of Ca 125 as tumor marker in ovarian carcinoma. Obstet Gynecol. 1986 Apr;67(4):473–477. [PubMed] [Google Scholar]
  15. Lavin P. T., Knapp R. C., Malkasian G., Whitney C. W., Berek J. C., Bast R. C., Jr CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987 Feb;69(2):223–227. [PubMed] [Google Scholar]
  16. Markman M. A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer. Gynecol Oncol. 1993 Dec;51(3):297–298. doi: 10.1006/gyno.1993.1292. [DOI] [PubMed] [Google Scholar]
  17. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  18. Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995 Aug;86(2):259–264. doi: 10.1016/0029-7844(95)00126-c. [DOI] [PubMed] [Google Scholar]
  19. Ng L. W., Homesley H. D., Barrett R. J., Welander C. E., Case L. D. CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer. Am J Clin Oncol. 1989 Apr;12(2):106–109. doi: 10.1097/00000421-198904000-00003. [DOI] [PubMed] [Google Scholar]
  20. Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649–655. [PubMed] [Google Scholar]
  21. Pearl M. L., Yashar C. M., Johnston C. M., Reynolds R. K., Roberts J. A. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol. Gynecol Oncol. 1994 Jun;53(3):339–343. doi: 10.1006/gyno.1994.1144. [DOI] [PubMed] [Google Scholar]
  22. Rustin G. J., Nelstrop A. E., McClean P., Brady M. F., McGuire W. P., Hoskins W. J., Mitchell H., Lambert H. E. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996 May;14(5):1545–1551. doi: 10.1200/JCO.1996.14.5.1545. [DOI] [PubMed] [Google Scholar]
  23. Rustin G. J., Nelstrop A. E., Tuxen M. K., Lambert H. E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996 Apr;7(4):361–364. doi: 10.1093/oxfordjournals.annonc.a010602. [DOI] [PubMed] [Google Scholar]
  24. Rustin G. J., Nelstrop A., Stilwell J., Lambert H. E. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer. 1992;28(1):79–82. doi: 10.1016/0959-8049(92)90390-n. [DOI] [PubMed] [Google Scholar]
  25. Rustin G. J., van der Burg M. E., Berek J. S. Advanced ovarian cancer. Tumour markers. Ann Oncol. 1993;4 (Suppl 4):71–77. [PubMed] [Google Scholar]
  26. Sevelda P., Schemper M., Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1989 Nov;161(5):1213–1216. doi: 10.1016/0002-9378(89)90668-6. [DOI] [PubMed] [Google Scholar]
  27. Sier C. F., Stephens R., Bizik J., Mariani A., Bassan M., Pedersen N., Frigerio L., Ferrari A., Danø K., Brünner N. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998 May 1;58(9):1843–1849. [PubMed] [Google Scholar]
  28. Skates S. J., Xu F. J., Yu Y. H., Sjövall K., Einhorn N., Chang Y., Bast R. C., Jr, Knapp R. C. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995 Nov 15;76(10 Suppl):2004–2010. doi: 10.1002/1097-0142(19951115)76:10+<2004::aid-cncr2820761317>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  29. Tuxen M. K., Sölétormos G., Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995 May;21(3):215–245. doi: 10.1016/0305-7372(95)90002-0. [DOI] [PubMed] [Google Scholar]
  30. Woolas R. P., Conaway M. R., Xu F., Jacobs I. J., Yu Y., Daly L., Davies A. P., O'Briant K., Berchuck A., Soper J. T. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol. 1995 Oct;59(1):111–116. doi: 10.1006/gyno.1995.1276. [DOI] [PubMed] [Google Scholar]
  31. Woolas R. P., Xu F. J., Jacobs I. J., Yu Y. H., Daly L., Berchuck A., Soper J. T., Clarke-Pearson D. L., Oram D. H., Bast R. C., Jr Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993 Nov 3;85(21):1748–1751. doi: 10.1093/jnci/85.21.1748. [DOI] [PubMed] [Google Scholar]
  32. Xu F. J., Yu Y. H., Daly L., DeSombre K., Anselmino L., Hass G. M., Berchuck A., Soper J. T., Clarke-Pearson D. L., Boyer C. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J Clin Oncol. 1993 Aug;11(8):1506–1510. doi: 10.1200/JCO.1993.11.8.1506. [DOI] [PubMed] [Google Scholar]
  33. van der Burg M. E., Lammes F. B., Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol. 1990 Jul;1(4):301–302. doi: 10.1093/oxfordjournals.annonc.a057754. [DOI] [PubMed] [Google Scholar]
  34. van der Burg M. E., Lammes F. B., van Putten W. L., Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988 Jul;30(3):307–312. doi: 10.1016/0090-8258(88)90244-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES